OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial

OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention of recurrent, fully resected, lung metastatic osteosarcoma.

Results indicated that the candidate met its primary endpoint of 12-month event-free survival. OST-HER2 had